title: Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma.
abstract: The clinical efficacy of rituximab therapy in systemic mucosa-associated lymphoid tissue (MALT) lymphoma with both periocular and intraocular involvement is described. Ophthalmic examination and radiologic imaging demonstrated tumor with bilateral periorbital, lacrimal, and subconjunctival infiltration, a pseudohypopyon in one eye, and extensive systemic lymph node involvement. Lymph node biopsy confirmed the pathologic findings of a low-grade MALT lymphoma. The patient had a complete remission within 3 months of starting rituximab therapy. A recurrence 6 months later remitted with a second round of rituximab therapy and the patient remained tumor-free at 1 year.
authors.affiliation: Florida Eye Specialists, Jacksonville, Florida 32256, USA. rkshetty1@yahoo.com
authors.forename: Rajesh K
authors.initials: RK
authors.lastname: Shetty
authors.forename: Benjamin H
authors.initials: BH
authors.lastname: Adams
authors.forename: Han W
authors.initials: HW
authors.lastname: Tun
authors.forename: Brandon R
authors.initials: BR
authors.lastname: Runyan
authors.forename: David M
authors.initials: DM
authors.lastname: Menke
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Broderick
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D004359:Drug Therapy, Combination; D005134:Eye Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D000077338:Latanoprost; D000069559:Loteprednol Etabonate; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D010307:Parotid Neoplasms / Q000556:secondary; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D000069283:Rituximab; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013999:Timolol / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000069283:Rituximab; D000068438:Brimonidine Tartrate; D000077338:Latanoprost; D013999:Timolol; C062765:dorzolamide; D000069559:Loteprednol Etabonate